Modality
Fusion Protein
MOA
TNFi
Target
PARP
Pathway
Ferroptosis
Huntington's
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
Jun 2017
→ Dec 2029
Phase 3Current
NCT05337675
159 pts·Huntington's
2024-08→2029-12·Not yet recruiting
NCT03953513
1,396 pts·Huntington's
2017-06→2028-10·Terminated
NCT07706997
38 pts·Huntington's
2022-04→2029-03·Completed
+1 more trial
2,934 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2028-10-192.6y awayPh3 Readout· Huntington's
2029-03-243.0y awayPh3 Readout· Huntington's
2029-12-133.7y awayPh3 Readout· Huntington's
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Termina…
P3
Termina…
P3
Complet…
P3
Not yet…
Catalysts
Ph3 Readout
2028-10-19 · 2.6y away
Huntington's
Ph3 Readout
2029-03-24 · 3.0y away
Huntington's
Ph3 Readout
2029-12-13 · 3.7y away
Huntington's
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05337675 | Phase 3 | Huntington's | Not yet recr... | 159 | HAM-D |
| NCT03953513 | Phase 3 | Huntington's | Terminated | 1396 | PANSS |
| NCT07706997 | Phase 3 | Huntington's | Completed | 38 | SeizFreq |
| NCT05062280 | Phase 3 | Huntington's | Terminated | 1341 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP |